Literature DB >> 21876079

Chek2 DNA damage response pathway and inherited breast cancer risk.

Nadine Tung1, Daniel P Silver.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21876079     DOI： 10.1200/JCO.2011.37.1476

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  Association of CHEK2 polymorphisms with the efficacy of platinum-based chemotherapy for advanced non-small-cell lung cancer in Chinese never-smoking women.

Authors:  Wen Xu; Di Liu; Yang Yang; Xi Ding; Yifeng Sun; Baohong Zhang; Jinfu Xu; Bo Su
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

2.  Cancer risk assessment using genetic panel testing: considerations for clinical application.

Authors:  Susan Hiraki; Erica S Rinella; Freya Schnabel; Ruth Oratz; Harry Ostrer
Journal:  J Genet Couns       Date:  2014-03-07       Impact factor: 2.537

3.  Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.

Authors:  Mieke Kriege; Agnes Jager; Antoinette Hollestelle; Els M J J Berns; Jannet Blom; Marion E Meijer-van Gelder; Anieta M Sieuwerts; Ans van den Ouweland; J Margriet Collée; Judith R Kroep; John W M Martens; Maartje J Hooning; Caroline Seynaeve
Journal:  J Cancer Res Clin Oncol       Date:  2015-05-10       Impact factor: 4.553

Review 4.  CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer.

Authors:  Victoria Hale; Maren Weischer; Jong Y Park
Journal:  Prostate Cancer       Date:  2014-11-06

5.  Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer.

Authors:  Emmanuelle Nicolas; Sanjeevani Arora; Yan Zhou; Ilya G Serebriiskii; Mark D Andrake; Elizabeth D Handorf; Dale L Bodian; Joseph G Vockley; Roland L Dunbrack; Eric A Ross; Brian L Egleston; Michael J Hall; Erica A Golemis; Veda N Giri; Mary B Daly
Journal:  Oncotarget       Date:  2015-11-24

6.  Homozygous inactivation of CHEK2 is linked to a familial case of multiple primary lung cancer with accompanying cancers in other organs.

Authors:  Yoji Kukita; Jiro Okami; Noriko Yoneda-Kato; Ikuko Nakamae; Takeshi Kawabata; Masahiko Higashiyama; Junya Kato; Ken Kodama; Kikuya Kato
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-11

7.  Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines.

Authors:  Nandita Barnabas; Dalia Cohen
Journal:  Int J Breast Cancer       Date:  2013-01-16

8.  Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.

Authors:  M Kriege; A Hollestelle; A Jager; P E A Huijts; E M Berns; A M Sieuwerts; M E Meijer-van Gelder; J M Collée; P Devilee; M J Hooning; J W M Martens; C Seynaeve
Journal:  Br J Cancer       Date:  2014-06-10       Impact factor: 7.640

9.  Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer.

Authors:  Emma R Woodward; Elke M van Veen; Claire Forde; Elaine F Harkness; Helen J Byers; Jamie M Ellingford; George J Burghel; Helene Schlech; Naomi L Bowers; Andrew J Wallace; Sacha J Howell; Anthony Howell; Fiona Lalloo; William G Newman; Miriam J Smith; D Gareth Evans
Journal:  Genet Med       Date:  2021-06-10       Impact factor: 8.822
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.